On-Body Injector: An Administration Device for Pegfilgrastim

Clin J Oncol Nurs. 2017 Feb 1;21(1):121-122. doi: 10.1188/17.CJON.121-122.

Abstract

Many chemotherapy regimens used today require the support of a granulocyte-colony-stimulating factor for the prevention of life-threatening neutropenia. In March 2015, a delivery method was introduced for Neulasta® (pegfilgrastim) through an on-body injector (Onpro®), which may eliminate the need for patients to return for injection after chemotherapy, increase workflow, and allow more patients to be seen. The purpose of this study was to monitor the implementation of the Onpro delivery system in an outpatient facility.

Keywords: febrile neutropenia; on-body injector; patient satisfaction; pegfilgrastim.

Publication types

  • Evaluation Study

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Cohort Studies
  • Drug Delivery Systems / instrumentation*
  • Female
  • Filgrastim / administration & dosage*
  • Hematologic Agents / administration & dosage
  • Humans
  • Injections, Subcutaneous / instrumentation*
  • Male
  • Neoplasms / diagnosis
  • Neoplasms / drug therapy
  • Neutropenia / etiology
  • Neutropenia / prevention & control*
  • Oncology Nursing / education
  • Patient Education as Topic / methods
  • Patient Safety*
  • Patient Satisfaction / statistics & numerical data
  • Retrospective Studies

Substances

  • Hematologic Agents
  • Filgrastim